DalsnaFinance Account

Rxo Inc $RXO

Industrials

Russell 2000 North Carolina

Create a scorecard

$28.67

+0.17 (+0.60%)

As of Oct 20, 2026, 7:29 PM EDT · cached

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 6, 2026, the first target we tracked for RXO.

Rxo Inc (RXO) is trading up at $28.67 (+0.60%), as of the latest quote. It is a Russell 2000 constituent in the Industrials sector.

Analyst price targets on RXO

Current price targets from 3 firms average $30.2, median $30.3, ranging from $30 to $30.3 — the average is 5% above the current $28.7. Each is tracked to its date and scored the same way a member's call is.

BMO Capital Markets $28.6 → $30.3 by Oct 2027 Market Perform Oct 6, 2026 via Investing.com · BMO Capital Markets's track record
JPMorgan $28.6 → $30 by Oct 2027 Neutral Oct 6, 2026 via Investing.com · JPMorgan's track record
TD Cowen $28.6 → $30.3 by Oct 2027 Hold Oct 6, 2026 via Investing.com · TD Cowen's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Rxo Inc revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)

Rxo Inc annual financial statements
	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$3.36B	$4.69B	$4.80B	$3.93B	$4.55B	$5.74B
Growth (year over year)	—	+39.7%	+2.3%	−18.1%	+15.9%	+26.2%
Gross profit	$789.0M	$1.01B	$1.17B	$960.0M	$985.0M	$1.13B
Gross margin	23.5%	21.5%	24.4%	24.4%	21.6%	19.7%
Operating income	$60.0M	$192.0M	$123.0M	$39.0M	−$56.0M	−$79.0M
Operating margin	1.8%	4.1%	2.6%	1.0%	−1.2%	−1.4%
Net income	$43.0M	$150.0M	$92.0M	$4.00M	−$290.0M	−$100.0M
Net margin	1.3%	3.2%	1.9%	0.1%	−6.4%	−1.7%
EPS (diluted)	$0.37	$1.30	$0.79	$0.03	−$2.17	−$0.59
Balance sheet
Cash and equivalents	$70.0M	$29.0M	$98.0M	$5.00M	$35.0M	$17.0M
Total assets	—	$2.07B	$2.03B	$1.82B	$3.41B	$3.28B
Total liabilities	—	$998.0M	$1.44B	$1.23B	$1.80B	$1.74B
Long-term debt	—	$0	$451.0M	$356.0M	$351.0M	$387.0M
Shareholders' equity	$1.07B	$1.07B	$587.0M	$594.0M	$1.61B	$1.54B
Cash flow
Operating cash flow	$25.0M	$155.0M	$310.0M	$89.0M	−$12.0M	$51.0M
Capital expenditure	$47.0M	$39.0M	$57.0M	$64.0M	$45.0M	$59.0M
Free cash flow	−$22.0M	$116.0M	$253.0M	$25.0M	−$57.0M	−$8.00M
Share buybacks	—	$0	$0	$2.00M	$0	$0

RevenueNet incomeNet margin (right axis, %)

Rxo Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$1.04B	$1.67B	$1.43B	$1.42B	$1.42B	$1.47B	$1.43B	$1.77B
Growth (year over year)	+6.6%	+70.4%	+57.0%	+52.6%	+36.6%	−11.9%	−0.6%	+25.0%
Gross profit	$231.0M	$310.0M	$280.0M	$301.0M	$284.0M	$266.0M	$254.0M	$302.0M
Gross margin	22.2%	18.6%	19.5%	21.2%	20.0%	18.1%	17.8%	17.0%
Operating income	−$20.0M	−$24.0M	−$30.0M	$0	−$7.00M	−$42.0M	−$28.0M	$1.00M
Operating margin	−1.9%	−1.4%	−2.1%	0.0%	−0.5%	−2.9%	−2.0%	0.1%
Net income	−$243.0M	−$25.0M	−$31.0M	−$9.00M	−$14.0M	−$46.0M	−$36.0M	−$9.00M
Net margin	−23.4%	−1.5%	−2.2%	−0.6%	−1.0%	−3.1%	−2.5%	−0.5%
EPS (diluted)	−$1.81	−$0.17	−$0.18	−$0.05	−$0.08	−$0.28	−$0.21	−$0.05
Balance sheet
Cash and equivalents	$55.0M	$35.0M	$16.0M	$18.0M	$25.0M	$17.0M	$21.0M	$15.0M
Total assets	$3.39B	$3.41B	$3.30B	$3.20B	$3.20B	$3.28B	$3.27B	$3.46B
Total liabilities	$1.74B	$1.80B	$1.72B	$1.61B	$1.62B	$1.74B	$1.76B	$1.95B
Long-term debt	$352.0M	$351.0M	$387.0M	$387.0M	$387.0M	$387.0M	$430.0M	$459.0M
Shareholders' equity	$1.65B	$1.61B	$1.59B	$1.59B	$1.58B	$1.54B	$1.51B	$1.51B
Cash flow
Operating cash flow	−$7.00M	−$7.00M	−$2.00M	$23.0M	$23.0M	$7.00M	−$7.00M	−$40.0M
Capital expenditure	$11.0M	$12.0M	$15.0M	$14.0M	$14.0M	$16.0M	$17.0M	$12.0M
Free cash flow	−$18.0M	−$19.0M	−$17.0M	$9.00M	$9.00M	−$9.00M	−$24.0M	−$52.0M
Share buybacks	$0	$0	—	—	—	—	—	—

From Rxo Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →